Mode
Text Size
Log in / Sign up

Higher AMH levels in PCOS patients correlate with higher oocyte yields and increased OHSS riskAMH hormone levels impact pregnancy success for women with PCOS

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher AMH levels correlate with increased oocyte yields but also significantly increase OHSS risk in PCOS patients.

This systematic review and meta-analysis evaluates the impact of anti-Müllerian hormone (AMH) levels on pregnancy outcomes and safety markers in women with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology (ART). The study stratified patients into low, medium, and high AMH groups to determine how these levels influence clinical outcomes.

The meta-analysis found that higher oocyte yields were associated with ascending AMH subgroups (low vs. high: MD = -3.91; low vs. medium: MD = -2.33; medium vs. high: MD = -1.70). However, higher AMH levels were significantly associated with an increased risk of ovarian hyperstimulation syndrome (OHSS) (high vs. low: OR = 0.64; high vs. medium: OR = 0.40). In contrast, the lower AMH group showed higher live birth rates compared to medium and high groups (low vs. medium: RR = 1.15; low vs. high: RR = 1.19) and a lower risk of miscarriage (low vs. medium: RR = 0.60; low vs. high: RR = 0.72).

No significant associations were found between AMH levels and cumulative live birth rates, clinical pregnancy rates, or the number of good-quality embryos. The authors suggest that using a three-tier stratification for AMH provides more nuanced information regarding reproductive outcomes and OHSS risk than binary classification. These findings are associated rather than causal.

How this fits prior evidence

This meta-analysis addresses a gap in understanding how specific hormonal markers influence ART outcomes in PCOS patients. While previous evidence has identified risks such as a 24% prevalence of Gestational Diabetes Mellitus in this population and the role of various supplements or medications like astaxanthin, GLP-1 receptor agonists, and metformin for management, this study specifically focuses on AMH levels to refine risk stratification for OHSS and pregnancy success.

For many women with Polycystic Ovary Syndrome (PCOS), the road to pregnancy involves assisted reproductive technology. A new look at these cases reveals that Anti-Müllerian Hormone (AMH) levels provide important clues about what to expect during treatment.

While higher AMH levels were linked to a greater number of eggs retrieved, they also came with a significant risk of Ovarian Hyperstimulation Syndrome (OHSS). This is a condition where the ovaries overreact to fertility medications. In contrast, women with lower AMH levels showed higher live birth rates and a lower risk of miscarriage compared to those with medium or high levels.

It is important to remember that these findings show an association between hormone levels and outcomes, not a direct cause. While cumulative pregnancy rates and the number of high-quality embryos did not change based on AMH levels, knowing where a patient falls on the low, medium, or high scale helps doctors provide more tailored care.

What this means for you:
Lower AMH levels are linked to higher live birth rates and lower miscarriage risks in women with PCOS.

Common questions

How do AMH levels affect the number of eggs collected?

The study found that higher AMH levels were associated with more eggs (oocytes) being retrieved. Specifically, the low group had significantly fewer eggs compared to both the medium and high groups.

Is there a risk of OHSS for women with PCOS?

Yes, higher AMH levels were linked to an increased risk of Ovarian Hyperstimulation Syndrome (OHSS). This is a condition where the ovaries overreact to fertility medications.

Do AMH levels affect the chance of a live birth?

Women with lower AMH levels showed higher live birth rates compared to those in the medium and high groups. However, there was no significant link between AMH levels and clinical pregnancy rates or the number of good-quality embryos.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BackgroundAnti-Müllerian hormone (AMH) is typically elevated in women with polycystic ovary syndrome (PCOS), but its relationship with assisted reproductive technology (ART) outcomes remains unclear.ObjectivesThis systematic review and meta-analysis aimed to evaluate the association between AMH levels and pregnancy outcomes in women with PCOS undergoing ART.Search methodsObservational studies published between January 2020 and May 2025 were identified from major databases. The search strategy incorporated controlled vocabulary and keywords related to “Polycystic Ovary Syndrome,” “anti-Müllerian hormone,” and ART outcomes. Eight studies were included.Main outcomesHigher oocyte yields were observed across ascending AMH subgroups, with significant differences detected in all pairwise comparisons (low vs. high: MD = −3.91, 95% CI: −5.60 to −2.23; Z = 4.55, P < 0.001, I2 = 86%; low vs. medium: MD = −2.33, 95% CI: −2.79 to −1.86; Z = 9.77, P < 0.001, I2 = 50%; medium vs. high: MD = −1.70, 95% CI: −3.31 to −0.09; Z = 2.07, P = 0.04, I2 = 0%). Higher AMH levels were significantly associated with increased risk of ovarian hyperstimulation syndrome (OHSS). Compared with the low AMH group, the high AMH group had a higher OHSS risk (OR = 0.64, 95% CI: 0.47–0.88, Z = 2.77, P = 0.006, I2 = 0%). Similarly, the high AMH group also presented a significantly elevated OHSS risk relative to the medium AMH group (OR = 0.40, 95% CI: 0.23–0.70, Z = 3.19, P = 0.006, I2 = 0%). Paradoxically, reproductive outcomes appear more favorable in participants with lower AMH levels: low AMH was associated with higher live birth rates versus both medium (RR = 1.15, 95% CI: 1.07–1.24; Z = 3.71, < 0.001, I2 = 39%) and high AMH (RR = 1.19, 95% CI: 1.10–1.28; Z = 4.53, P < 0.001, I2 = 27%), as well as a lower miscarriage risk (low vs. medium: RR = 0.60, 95% CI: 0.42–0.86; Z = 2.80, P = 0.005, I2 = 0%; low vs. high: RR = 0.72, 95% CI: 0.53–0.98; Z = 2.10, P = 0.04, I2 = 49%). No significant associations were found between AMH levels and cumulative live birth rates, clinical pregnancy rates, or number of good-quality embryos.ConclusionThe distinct intermediate phenotype of the medium AMH group, exhibiting superior live birth outcomes compared to high AMH, yet inferior to low AMH, underscores the value of finer stratification beyond a simple binary classification.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier [CRD420251089070].
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.